|
|
||||||||
Article |
Clinical Chemistry Service, Clinical Pathology Department, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bldg. 10, Rm. 2C-306, 10 Center Dr., MSC 1508, Bethesda, MD 20892-1508.
a Author for correspondence. Fax 301-402-1885; e-mail nrehak{at}cc.nih.gov
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In the US, only the AVL and Nova Mg ISEs are approved by the Food and Drug Administration for clinical application. However, the accuracy of each method has not yet been determined, because of the lack of a reference material. Further, the interpretation of iMg results is not clearly established, especially in relation to tMg. Most of the studies with the Nova Mg ISE were reported by Altura et al., who found a decreased iMg associated with "normal" tMg (values within the reference range) in patients with several different pathological abnormalities (reviewed in ref. (4)) and in healthy male adults (5). Wu et al. (6) also reported low Nova iMg results associated with normal tMg in alcoholic patients admitted to the emergency department of a trauma hospital. In our studies of patients undergoing treatment with IL-2 (7) and of patients with chronic alcohol consumption (8), many patients also had a normal serum tMg and an abnormally low Nova iMg result. However, of 56 samples with this combination of results, only 2 had an abnormally low AVL iMg result. When we performed a comparison study between the AVL and Nova iMg methods with serum samples from randomly selected patients for which Nova or AVL iMg results were abnormal (9), all samples with normal tMg and abnormally low Nova iMg results (n = 25) again had normal AVL iMg results, and we suggested the possibility of interfering substances as a cause of the intermethod discrepancies. Because we also found significant intermethod differences with samples from apparently healthy individuals (10), we reviewed, retrospectively, the demographic information for each donor included in that study. We found that the cigarette smoking habit of a donor correlated with the observed intermethod differences.
Two major components of tobacco smoke are found to be increased in serum of smokers, nicotine and thiocyanate (SCN). Nicotine appears in the blood shortly after smoking and is metabolized to cotinine (11), the half-life of nicotine being ~2 h and of cotinine 1020 h (12). SCN is the metabolite of hydrogen cyanide and organic cyanides; ~40% of the circulating SCN is bound to albumin (13), and the half-life is relatively long (~14 days) (14). Because of this relatively long half-life, the serum concentration of SCN does not change as rapidly as that of nicotine or cotinine. Further, SCN has been considered a useful marker for the assessment of exposure to tobacco smoke (15)(16)(17). However, SCN is also present in the serum of nonsmokers, given that cyanide is produced by the metabolism of vitamin B12 and of foods that contain cyanide or cyanogenic glucosides (e.g., cabbage, broccoli, almonds) (18).
In this study, we have investigated the effect of SCN on the AVL and Nova Mg ISEs. Because the albumin-bound SCN would be less likely to interact with the sensor of an ISE, we limited our investigation to the free, ionic form (SCN-).
| Materials and Methods |
|---|
|
|
|---|
Analyzers.
The Nova Biomedical CRT and the AVL (Graz,
Austria) 9884 analyzers, previously described (10), were
used to determine iMg and ionized calcium (iCa). For the aqueous
samples, the voltage responses of the Nova Mg and Ca ISEs were also
recorded. The Hitachi 917 (Boehringer Mannheim) analyzer was used to
determine serum concentrations of tMg and total calcium (tCa). The
Cobas Fara (Roche) was used to determine the concentration of
SCN- (measurement mode: ABS; reaction mode: S-I-R1-A;
calibration mode: linear regression; reagent blank: REAG/DIL;
wavelength: 460 nm; temperature: 37 °C; sample volume: 80 µL;
diluent (H2O) volume: 15 µL; ferric nitrate volume: 100
µL; incubation time: 10 s; first reading: 10 s; number of
readings: 6; interval: 10 s; calculation: endpoint; first: M1;
last: 6; calibration: each run). The method was an adaptation of the
ferric nitrate chromogen method (19).
Procedures.
The effect of SCN- on the ISEs
was determined with MgCl2/CaCl2 saline
solutions and pooled serum, with or without added MgCl2.
Each test solution was prepared with and without added stock KSCN in
saline, which was then mixed to prepare a series of solutions with
increasing SCN- concentration as described previously
(20).
Blood samples from apparently healthy smokers (n = 20) and nonsmokers (n = 20) were collected anaerobically in Vacutainer Tubes with glycerin as a stopper lubricant (Becton-Dickinson) after informed consent. All procedures were in accordance with the ethical standards laid down in the Helsinki Declaration of 1975, as revised in 1983. Serum SCN- was determined by assaying the serum ultrafiltrates, obtained with a Centricon-30 (30 000 Mr cutoff; Amicon). All SCN- results reported in this study are the mean values of duplicate determinations.
Statistics.
Linear regression was used to investigate
association between the iMg, iCa, and SCN- results.
P <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
0.20 mmol/L, the recovery remained constant (6367%). This
recovery indicates that 3337% of SCN- in serum was
bound, which is similar to the ~40% binding of SCN- to
serum albumin reported previously (13).
The effect of SCN- on the Nova and AVL iMg and iCa
results for a pooled serum with added MgCl2 is shown in
Fig. 1
. The baseline SCN- concentration was 0.020 mmol/L.
The AVL results for both iCa and iMg and the Nova iCa results were not
affected by SCN- but the Nova iMg results decreased with
increasing concentrations of SCN-. The relationship
between iMg results and SCN- concentration was best
characterized by a second-order polynomial regression.
|
A similar nonlinear relationship between the Nova iMg results and the
SCN- concentrations was observed with the saline
solutions (Fig. 2
). As with the pooled serum, the AVL results and the Nova iCa results
were not affected. The Nova iMg results decreased, the extent of change
depending on the initial iMg value [iMg(init)] determined in the
absence of SCN-. This dependence was also observed with
the serum samples. The change for the pooled serum with iMg(init) =
0.94 mmol/L (constant iCa = 1.23 mmol/L) is similar to the change
for saline with iMg(init) = 0.99 mmol/L (constant iCa = 1.22
mmol/L), whereas the change for sera (n = 5) with iMg(init)
between 0.39 and 0.48 mmol/L (iCa 0.871.01 mmol/L) was similar to the
change for saline with iMg(init) = 0.43 mmol/L (constant iCa = 1.0
mmol/L; see Fig. 2
). We found that in saline, in the absence of Mg
ions, and at a constant concentration of Ca ions (1, 2, or 3 mmol/L),
the mV response of the Mg ISE was affected by SCN-. An
increase in the SCN-concentration from 0 (baseline) to
0.20 mmol/L caused a decrease in the mV response of 1.90 (iCa = 1
mmol/L), 2.11 (iCa = 2 mmol/L), and 2.78 (iCa = 3 mmol/L)
from the baseline. This decrease was associated with a decrease in the
iMg result from 0.17 to 0.11, from 0.26 to 0.15, and from 0.35 to 0.17
mmol/L, respectively.
|
The serum tCa, tMg, iCa, and iMg concentrations for the apparently
healthy nonsmokers (n = 20) and smokers (n = 20) were within
the reference intervals established in our laboratory for each method.
The mean (range) serum SCN- concentration was 0.019
(0.0080.046) mmol/L for the nonsmokers and 0.077 (0.0200.138)
mmol/L for the smokers. The iCa results were not affected by
SCN- (y = -0.16x + 1.20,
r2 = 0.035, P >0.1 for
Nova; y = -0.117x + 1.29,
r2 = 0.02, P >0.3 for AVL). The
relation between the serum AVL and Nova iMg results and the measured
SCN- concentration is shown in Fig. 3
A. The AVL results did not change, but the Nova results
decreased as the SCN- concentration increased and,
therefore, the difference between the iMg results determined by the two
methods increased (Fig. 3B
).
|
In addition, we determined the SCN- concentration in seven serum samples that were used in our original study of healthy individuals (10) and in serial samples of one patient treated with a high-dose IL-2 therapy (7). All of these samples had been stored in tightly capped vials at -20 °C for as long as 36 months. For the IL-2-treated patient, the SCN- ranged from 0.093 (day 1, just before administration of therapy) to 0.055 (3 days after administration of therapy) mmol/L. The corresponding Nova/AVL iMg results determined at the respective times of blood collection were 0.26/0.49 (tMg = 0.70) and 0.32/0.45 (tMg = 0.54) mmol/L. For the samples from healthy individuals, in six of the seven samples for which the intermethod difference for iMg was <-0.1 mmol/L, the SCN- was between 0.040 and 0.077 mmol/L. Three of these six samples were from self-reported cigarette smokers.
| Discussion |
|---|
|
|
|---|
Generally, the Nova iMg results were lower than the AVL results, which was reflected by a difference in our reported reference intervals for each method (0.390.64 mmol/L for Nova, 0.440.60 for AVL), even though the mean for both methods was the same (0.52 mmol/L) (10). The largest intermethod difference [iMg(diff) = Nova - AVL] observed for a healthy donor was -0.13 mmol/L. We also found significantly lower Nova results for patients undergoing IL-2 therapy (7) and individuals with chronic alcohol consumption (8). However, in both of these studies, the intermethod difference for individual samples varied greatly (from 0.10 to -0.47 mmol/L) and the abnormally low Nova results were often associated with a normal tMg concentration.
Interestingly, a close inspection of the Nova results for acute
alcoholics reported by Wu et al. (6) revealed the same
pattern: For individual samples with tMg between 0.8 and 1.0 mmol/L,
the iMg results ranged from ~0.21 (abnormally low) to ~0.55 mmol/L
(within the reference interval). This prompted us to compare the
abnormally low and high results for serum samples (excluding those for
alcoholics and IL-2 patients) that we determined with both the AVL or
Nova method. All 25 samples with Nova iMg
0.39 mmol/L (the lower
limit of the Nova reference interval) and normal tMg had normal AVL iMg
results (9). The intermethod difference (mean -0.19,
range 0.04 to -0.37 mmol/L) was not associated with the diagnosis of
the patient; however, many were outpatients, i.e., exposed to a
nonhospital environment. When we evaluated the health habits of
presumably healthy volunteers and of some patients in our studies, we
noted that cigarette smokers tended to have a low Nova iMg result.
These observations led us to the investigate the iMg results in
individuals who were smokers of cigarettes. We found that nicotine and
its metabolite, cotinine, had no effect on the measurements by either
of the Mg ISEs (21). However, we did see a significant
inverse correlation between the Nova iMg results and the leukocyte
count, which has previously been reported to be increased in smokers
(22). The observed intermethod difference for smokers
(mean -0.11, range -0.01 to -0.24 mmol/L) correlated directly with
the leukocyte count (21).
This study identifies SCN-, at concentrations found
in smokers, as an interferent with the Nova Mg ISE that causes
underestimation of the results. At physiologically normal iMg and iCa
concentrations, SCN- appears to cause an equimolar
decrease in the concentration of Mg ions (slope = -1.04, see Fig. 3
). However, from the results that we obtained with saline solutions
and pooled sera (see Fig. 2
), the SCN- concentration alone
cannot be used to accurately predict the actual decrease in the iMg
result. The most likely reason for this is the selectivity of the Mg
ISE to both the Mg and Ca ions. The chemometric correction for the
effect of Ca ions on the Mg ISE is based on the iCa result determined
with the Ca ISE. This correction would be erroneous if the response of
Mg ISE to Ca ions were affected by SCN- while, as we have
shown, the iCa result was not affected. The net effect would be
chemometric underestimation of the iMg concentration because of
overestimation of the Mg ISE response to Ca ions. We found that, in the
absence of Mg ions, the SCN- decreases the voltage
response of Mg ISE to Ca ions and, as a consequence, decreases the iMg
results. However, the significance of the observed change in the iMg
results attributable to this interference for Ca ions is difficult to
interpret. The results are generated by the chemometric calculation and
actually, if that calculation were proper, all iMg results in the
absence of SCN- should have been close to zero and
reported as "<0.1" (the linearity limit of the method). In light
of the observed decrease in the mV response of the Nova Mg ISE, we
suggest that SCN-, a lipophilic anion, decreases the slope
of the electrode response (mV/log [ion]) to both Mg and Ca ions. Such
an effect by SCN- has been reported for potassium and
calcium neutral carrier electrodes that did not have negatively charged
sites in the membrane (23). The addition of lipophilic
tetraphenyl borate anions into these membranes reduced the effect by
SCN- (and by other lipophilic anions) and also enhanced
the selectivity of membranes for the primary cations (24).
A similar effect of borate anions on the membrane selectivity was
reported for Mg electrodes with derivatized malondiamide subunits (ETH
compounds) as neutral carriers (25)(26). The
membrane of the AVL Mg ISE is based on ETH 7025 as the neutral carrier
with potassium tetrakis(p-chlorophenyl)borate as anionic
sites (1); this electrode was not affected by the presence
of SCN- in the sample. The composition of the Nova
membrane remains proprietary. However, we speculate that the observed
interference by SCN- may result from the absence of
anionic sites in the membrane of the Nova Mg ISE.
The intermethod differences we previously reported were most likely caused by increased concentrations of serum SCN-. Certainly, most of the alcoholic patients in our study (8) were known to be cigarette smokers. We do not have a complete demographic profile for each of the patients included in our study of abnormally low iMg results (9). However, the intermethod difference (mean -0.19, range 0.04 to -0.37 mmol/L) was similar to that observed in our study of smokers. In addition, the change in the serum SCN- for the patient treated with IL-2 (from 0.093 to 0.055 mmol/L) most likely reflects the cessation of smoking during hospitalization. For this patient, the tMg and the AVL iMg results decreased, but the Nova iMg results increaseda combination we have observed in several patients in our IL-2 study (7). Retrospectively, we can now also explain the much lower reference interval of the Nova iMg method (0.390.64 for Nova vs 0.4460 for AVL) that we determined previously with the results for both smokers and nonsmokers (10). We found that the SCN- concentration was increased in six of the seven samples from healthy donors for which the intermethod difference was -0.10 to -0.13 mmol/L, and three of these samples were collected from known cigarette smokers. This also explains why, in the present study, all Nova iMg results for the smokers are within the reference limits of that method.
We must point out that SCN- at serum concentrations
that can lead to negative interference with the Nova Mg ISE can be
attained not only from exposure to cigarette smoke but also from
dietary sources. Even with the small number of individuals in this
study, there was an overlap between the SCN-
concentrations for the nonsmokers and smokers, and the lowest
SCN- concentration for a nonsmoker was 0.008 mmol/L (see
Fig. 3
). Increased concentrations of total SCN were reported in two
nonsmokers who daily ingested cabbage (0.090 mmol/L) (23)
and raw brussel sprouts (0.080 mmol/L) (16). In both of
these cases, the concentration of the free SCN- (estimated
as ~0.0500.060 mmol/L) would be sufficient to cause an interference
with the Nova Mg ISE. Moreover, the number of cigarettes smoked/day and
the dietary habits can vary, as well as the serum SCN-
concentration. The fluctuation in the SCN- concentration
is unpredictable because of its long half-life. Therefore we suggest
that all Nova iMg results, especially the low ones, reported by us
(7)(8)(9)(10)(21) and by others (4)(5)(6)
are questionable. The findings by Altura et al. (5) that
low serum Nova iMg, but not tMg, concentrations for five healthy men
were a possible indicator of Mg deficit and a potential predictor of
future coronary vascular disease must be reexamined. Were these low iMg
results possibly caused by SCN- interference attributable
to smoking or dietary habits? Although the configuration of the
instrument used by Altura et al. (Nova Stat Profile) differed from that
used in the current study, the ionophore and membrane may be similar
and possibly also susceptible to the interference by SCN-.
The results of the present study lead us to suggest that the Nova Mg
ISE cannot provide reliable results suitable for clinical
interpretation. Thus, this method should not be used in a routine
patient care setting until the electrode is redesigned to eliminate the
observed interference by SCN-.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
J.-G. Wang, S. A. Mahmud, J. Nguyen, and A. Slungaard Thiocyanate-Dependent Induction of Endothelial Cell Adhesion Molecule Expression by Phagocyte Peroxidases: A Novel HOSCN-Specific Oxidant Mechanism to Amplify Inflammation J. Immunol., December 15, 2006; 177(12): 8714 - 8722. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhang, Z. Shen, W. M. Nauseef, and S. L. Hazen Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma Blood, March 1, 2002; 99(5): 1802 - 1810. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |